January 7, 2022
January 7, 2022 – Descovy® (emtricitabine/tenofovir alafenamide – Gilead) has been approved to treat HIV-1 infection in pediatric patients [weighing at least 14kg (31 pounds) and
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
GlobalReach Health
January 4, 2022
January 4, 2022 – Par Pharmaceutical has launched the first generic version of Merz Pharmaceuticals’
Cuvposa® (glycopyrrolate) oral solution. Both Cuvposa and its generic are indicated
December 30, 2021
December 30, 2021 – The U.S. FDA has approved Recorlev® (levoketoconazole), manufactured by Xeris Biopharma, to treat endogenous hypercortisolemia in adults diagnosed
December 28, 2021
December 28, 2022 – Leo Pharma's AdbryTM (tralokinumab-ldrm) has received FDA approval to treat moderate to severe atopic dermatitis in adults whose disease is not adequately
December 27, 2021
December 27, 2021 – Padagis US LLC has recalled three lots of nitroglycerin lingual spray due to a possible defect in the delivery system. Nitroglycerin lingual spray is indicated for
December 27, 2021
December 27, 2021 – Taro Pharmaceuticals has recalled one lot of Clobetasol Propionate Ointment USP, 0.05%, after identifying the presence of Ralstonia pickettii bacteria through
December 27, 2021
December 27, 2021 – Rexulti® (brexpiprazole – Otsuka Pharmaceutical) is now approved to treat schizophrenia in patients who are at least 13 years old. Previously, FDA approval
December 23, 2021
December 23, 2021 – Tascenso ODTTM (fingolimod) orally disintegrating tablets have been approved to treat relapsing forms of multiple sclerosis (MS) in pediatric patients who